Alitretinoin

drugbox
IUPAC_name = (2"E",4"E",6"Z",8"E")-3,7-dimethyl-9-(2,6,6-trimethyl-
1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid

---

CAS_number = 5300-03-8
ATC_prefix = L01
ATC_suffix = XX22
ATC_supplemental = ATC|D11|AX19 [cite web |url=http://www.whocc.no/atcddd/new_atc_ddd.html#ATCDDD_FINAL |title=ATC/DDD Classification (FINAL): New ATC 5th level codes |date=August 27, 2008 |author=WHO International Working Group for Drug Statistics Methodology |publisher=WHO Collaborating Centre for Drug Statistics Methodology |accessdate=2008-09-05]
PubChem = 449171
DrugBank = APRD00017
C = 20 | H = 28 | O = 2
molecular_weight = 300.435 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_UK =
legal_US =
legal_status = Rx only
routes_of_administration = Topical

Alitretinoin (tradename Panretin) is an antineoplastic agent developed by Ligand Pharmaceuticals.

It is a first generation retinoid.

Clinical uses

Alitretinoin is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. It is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using alitretinoin with systemic anti-KS treatment.

History

Ligand gained Food and Drug Administration (FDA) approval for alitretinoin in February 1999. Vol. 140 No. 12, December 2004 Archives • Online Features Under the trade name 'Toctino' it has been granted prescription rights in the UK (08/09/2008) for use in Chronic Hand Eczema. It is manufactured by Basilea of Switzerland. (BAL4079)Oral Alitretinoin (9-cis-Retinoic Acid) Therapy for Chronic Hand Dermatitis in Patients Refractory to Standard Therapy Results of a Randomized, Double-blind, Placebo-Controlled, Multicenter Trial

Thomas Ruzicka, MD; Frederik Grønhøj Larsen, MD, PhD; Dorota Galewicz, MD; Attila Horváth, MD; Peter Jan Coenraads, MD; Kristian Thestrup-Pedersen, MD; Jean Paul Ortonne, MD; Christos C. Zouboulis, MD; Martin Harsch, PhD; Thomas C. Brown, PhD; Maurice Zultak, MD

Arch Dermatol. 2004;140:1453-1459.

References

External links

* [http://www.eisai.com/pdf_files/Pgel%20PI%20rev-1%20ver-1%20feb07.pdf Prescribing Information] (revised February 2007). Retrieved on 01-30-08.